Clinical bottom line
Acute variceal hemorrhage (AVH) in cirrhosis remains a life-threatening emergency requiring prompt, multidisciplinary management. Recent updates in guidelines emphasize early vasoactive therapy, timely endoscopic intervention, and antibiotic prophylaxis to improve hemostasis and reduce infectious complications. Advances in risk stratification and individualized care, including etiological treatment of underlying liver disease, are refining management strategies. Despite improvements, high mortality persists in advanced cirrhosis, underscoring the need for ongoing optimization of therapeutic protocols (Lesmana et al., 2025; Brown et al., 2025).
What the evidence shows
Management of AVH centers on rapid stabilization, control of bleeding, and prevention of rebleeding. Lesmana et al. (2025) in the updated APASL guidelines recommend early initiation of vasoactive agents such as terlipressin or somatostatin analogs upon suspicion of variceal bleeding, ideally before endoscopy.
Endoscopic variceal ligation (EVL) remains the gold standard for hemostasis, with Talwalkar et al. (2010) emphasizing quality characteristics of endoscopy including timing within 12 hours and skilled technique to optimize outcomes.
Antibiotic prophylaxis is critical to prevent bacterial infections that worsen prognosis; Fernández et al. (2014) demonstrated reduced mortality and rebleeding rates with short-course intravenous antibiotics.
Lisman et al. (2022) highlight the complex haemostatic alterations in cirrhosis, advocating for cautious correction of coagulopathy and platelet dysfunction tailored to bleeding risk.
Etiological therapy targeting underlying liver disease, as discussed by Hu et al. (2020), plays an important role in long-term management to reduce portal hypertension and variceal recurrence.
Jakab et al. (2020) provide a comprehensive overview of esophageal and gastric varices evaluation, underscoring the importance of surveillance and secondary prophylaxis.
Ibrahim et al. (2020) review practical aspects of AVH management, including transfusion strategies favoring restrictive approaches to maintain hemoglobin around 7-8 g/dL.
Caveats and uncertainty
Despite guideline recommendations, variability exists in timing and choice of vasoactive agents and antibiotics across centers.
Optimal transfusion thresholds and correction of coagulation parameters remain debated, with limited high-quality randomized data.
Endoscopy access and expertise may delay intervention in some settings, impacting outcomes.
The role of emerging therapies such as early transjugular intrahepatic portosystemic shunt (TIPS) placement requires further validation in diverse populations.
Long-term management strategies depend heavily on liver disease stage and comorbidities, complicating standardized approaches.
How this may change practice
Early recognition and initiation of vasoactive drugs in suspected AVH should become standard practice, even pre-endoscopy.
Protocols ensuring rapid access to skilled endoscopy within 12 hours can improve hemostatic success.
Routine antibiotic prophylaxis should be integrated into AVH care pathways to reduce infectious complications.
Restrictive transfusion strategies and individualized haemostatic management may reduce adverse events.
Incorporation of etiological therapies and consideration of early TIPS in high-risk patients may improve survival.
Multidisciplinary care involving hepatology, gastroenterology, critical care, and interventional radiology is essential.
Ongoing education and quality improvement initiatives can enhance adherence to evidence-based guidelines.